Revenue
2010
2011
2012
2013
2014
2015
2016
2017
2018
2018
2019
2020
2021
2022
2023
2024
2025
EyePoint, Inc. (EYPT)
Price$4.58Cached quote
Net income
2010
2011
2012
2013
2014
2015
2016
2017
2018
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2010
2011
2012
2013
2014
2015
2016
2017
2018
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 · Dec 31 | 2018 · Jun 30 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.4M | $43.3M | $46.0M | $41.4M | $36.9M | $34.4M | $20.4M | $4.6M | $3.0M | $7.5M | $1.6M | $26.6M | $3.5M | $2.1M | $3.5M | $5.0M | $23.1M |
| Research & development | $221.0M | $132.9M | $64.7M | $49.6M | $28.5M | $17.4M | $15.4M | $18.5M | $16.2M | $14.9M | $14.4M | $12.1M | $9.6M | $7.0M | $7.0M | $6.9M | $7.0M |
| Operating expenses | $274.8M | $189.1M | $121.1M | $141.0M | $92.2M | $71.7M | $68.2M | $43.6M | $29.2M | $26.1M | $23.4M | $20.1M | $17.0M | $14.2M | $28.7M | $15.0M | $14.0M |
| Operating income | −$243.4M | −$145.9M | −$75.1M | −$99.6M | −$55.3M | −$37.3M | −$47.9M | −$39.0M | −$26.3M | −$18.6M | −$21.8M | $6.4M | −$13.5M | −$12.0M | −$25.2M | −$10.0M | $9.1M |
| Operating margin | −775.98% | −337.06% | −163.13% | −240.65% | −149.64% | −108.28% | −235.02% | −853.62% | −887.34% | −246.40% | −1,344.07% | 24.17% | −388.42% | −561.41% | −715.00% | −201.47% | 39.44% |
| EBITDA | −$241.1M | −$144.3M | −$74.6M | −$97.2M | −$52.5M | −$34.6M | −$45.3M | −$38.9M | −$25.1M | −$17.8M | −$20.9M | $7.3M | −$12.6M | −$11.0M | −$23.0M | −$6.6M | $12.4M |
| EBITDA margin | −768.62% | −333.50% | −162.12% | −234.74% | −142.14% | −100.59% | −222.23% | −851.50% | −848.56% | −235.59% | −1,288.02% | 27.49% | −362.02% | −515.03% | −651.84% | −133.90% | 53.86% |
| Net income | −$232.0M | −$130.9M | −$70.8M | −$102.3M | −$58.4M | −$45.4M | −$56.8M | −$86.1M | −$53.2M | −$18.5M | −$21.5M | $6.3M | −$13.4M | −$11.9M | −$24.8M | −$8.6M | $8.8M |
| Net profit margin | −739.42% | −302.43% | −153.84% | −246.97% | −158.14% | −131.82% | −278.88% | −1,884.16% | −1,795.71% | −245.19% | −1,330.06% | 23.89% | −384.54% | −555.30% | −704.34% | −173.78% | 37.97% |
| Basic EPSper basic share | -$3.17 | -$2.32 | -$1.82 | -$2.74 | -$2.03 | -$3.54 | -$5.44 | -$12.70 | -$11.50 | -$5.20 | -$6.80 | $2.20 | -$4.90 | -$5.20 | -$11.90 | -$4.40 | $4.80 |
| Diluted EPSper diluted share | -$3.17 | -$2.32 | -$1.82 | -$2.74 | -$2.03 | -$3.54 | -$5.44 | -$12.70 | -$11.50 | -$5.20 | -$6.80 | $2.10 | -$4.90 | -$5.20 | -$11.90 | -$4.40 | $4.60 |
Owners
Reported shareholders
9.76%of listed shares
MONTANOVA CAPITAL, LLC8.3M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
MONTANOVA CAPITAL, LLC | 9.76%8.3M shares |
BlackRock, Inc. | 8.78%7.46M shares |
Cormorant Asset Management, LP | 8.24%7M shares |
FEDERATED HERMES, INC. | 6.69%5.68M shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 5.68%4.83M shares |
FRANKLIN RESOURCES INC | 5.66%4.81M shares |
Commodore Capital LP | 5.41%4.6M shares |
Jupiter Topco LLC | 4.44%3.77M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.27%3.63M shares |
Paradigm Biocapital Advisors LP | 3.40%2.89M shares |
STATE STREET CORP | 2.77%2.36M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.43%2.06M shares |
Aberdeen Group plc | 2.36%2.01M shares |
CITADEL ADVISORS LLC | 2.33%1.98M shares |
Balyasny Asset Management L.P. | 2.13%1.81M shares |
Parkman Healthcare Partners LLC | 1.52%1.29M shares |
EVENTIDE ASSET MANAGEMENT, LLC | 1.47%1.25M shares |
TWO SIGMA INVESTMENTS, LP | 1.39%1.18M shares |
Essex Woodlands Management, Inc. | 1.28%1.08M shares |
ORBIMED ADVISORS LLC | 1.26%1.07M shares |
Percentages use 84.98M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 17, 2026Form 4 · 10b5-1 | Ribeiro RamiroChief Medical Officer | SellCommon Stock | 2.4K | $15.00 | $36.6K | 0 |
| Mar 16, 2026Form 4 | Duker Jay S.President and CEO | BuyCommon Stock · indirect | 1.5K | $13.15 | $19.7K | 100.7K |
| Mar 4, 2026Form 4 · 10b5-1 | Ribeiro RamiroChief Medical Officer | SellCommon Stock | 2.4K | $17.87 | $43.6K | 0 |
| Feb 17, 2026Form 4 · 10b5-1 | Ribeiro RamiroChief Medical Officer | SellCommon Stock | 2.4K | $15.00 | $36.6K | 0 |
| Jan 5, 2026Form 4 · 10b5-1 | Ribeiro RamiroChief Medical Officer | SellCommon Stock | 42.5K | $17.10 | $727.5K | 0 |